Q2 2024 · 13F-HR
SR ONE CAPITAL MANAGEMENT, LPholdings as filed
Filed 2024-08-13 · accession 0000950123-24-008225
$319.4M
Reported value
9
Positions
2024-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03940C100 | ACLXGBX | Arcellx, Inc. | $129.5M | 40.5% | 2,346,630 | Common | SOLE |
| H17182108 | CRSP | CRISPR Therapeutics AG | $56.7M | 17.7% | 1,048,951 | Common | SOLE |
| 82835W108 | SPRY | ARS Pharmaceuticals, Inc. | $34.1M | 10.7% | 4,012,903 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc. | $26.1M | 8.16% | 1,959,896 | Common | SOLE |
| 603170101 | MLYS | Mineralys Therapeutics Inc. | $23.6M | 7.39% | 2,016,822 | Common | SOLE |
| 25056L103 | DSGN | Design Therapeutics, Inc. | $21.9M | 6.85% | 6,526,476 | Common | SOLE |
| 65487U108 | NKTX | Nkarta, Inc. | $19.7M | 6.17% | 3,333,333 | Common | SOLE |
| 29286M105 | — | enGene Holdings Inc. | $4.7M | 1.48% | 500,000 | Common | SOLE |
| 483119202 | KALAEUR | KALA Bio, Inc. | $3.1M | 0.98% | 443,661 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.